Stifel Maintains Buy on SpyGlass Pharma, Raises Price Target to $44
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Stifel analyst Tom Stephan maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $44.
Stifel analyst Tom Stephan maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $44.
